🔗 Share this article

The recently developed medications for gonorrhoea in many years are being hailed as a "huge turning point" in the battle against drug-resistant strains of the pathogen, according to scientists.

A Global Health Concern

Cases of gonorrhoea are on the rise worldwide, with figures suggesting in excess of 82 million new cases per year. Particularly high rates are seen in the African continent and countries within the World Health Organization's Western Pacific region, which includes Mongolia and China to New Zealand. In England, cases have hit a historical peak, while infection numbers across Europe in 2023 were significantly elevated compared to those in 2014.

“The clearance of fresh medications for gonorrhoea is an important and timely development in the context of increasing worldwide cases, escalating drug resistance and the very limited treatment choices currently available.”

Health officials are increasingly worried about the surge in antibiotic-resistant strains. The World Health Organization has listed it as a "high-priority threat". A tracking program showed that the effectiveness of standard treatments like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

Recent Therapies Gain Authorization

Zoliflodacin, marketed under the name a brand name, was authorized by the US FDA in December for treating gonorrhoea. This infection can lead to significant complications, including infertility. Experts anticipate that targeted use of this new drug will help hinder the development of resistance.

Gepotidacin, developed by the pharmaceutical company GSK, also received approval in close succession. This treatment, which is also used to treat UTIs, was shown in trials to be effective against drug-resistant strains of the gonorrhoea bacteria.

A Unique Partnership

This new treatment stemmed from a innovative non-profit model for drug creation. The charitable organization Global Antibiotic Research & Development Partnership collaborated with the pharmaceutical company Innoviva to develop it.

“This milestone represents a huge turning point in the therapy of superbug gonorrhoea, which previously has been outpacing medical innovation.”

Testing Results and Worldwide Availability

According to data published in a prominent scientific publication, zoliflodacin eradicated over nine in ten of genital gonorrhoea infections. This establishes an similar efficacy with the typical regimen, which involves a dual-drug approach. The study involved over 900 volunteers from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its development partnership, GARDP has the rights to license and sell the drug in a wide range of developing nations.

Doctors on the front lines have expressed optimism. Access to a easy-to-administer therapy like this is described as a "game-changer" for managing the epidemic. This is considered vital to lessen the impact of the disease for people and to halt the transmission of untreatable gonorrhoea worldwide.